retatrutide a1c π¨Breaking: Retatrutide's first Phase 3 T2D data just dropped. βΈ A1C: β2.0% at 40 weeks βΈ Weight: β36.6 lbs (β16.8%) at 12 mg βΈ No weight loss plateau β curve still descending RETATRUTIDE: A Medication for Diabetes
Description
Morys-Wortmann C

A summary of clinically-significant GLP-1RAs described in this text and their clinical uses are listed in Table 1

Clinicians should discuss both options openly and consider the patients daily routine

P.PoulsenS

And I had patients that I had noticed that when they were living with depression or bipolar illness, if they were obese, if they were diabetic, if they had metabolic syndrome or some condition related to that, they were much more likely to have severe pathology

GLP-1 medications are not appropriate for everyone
